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The lipid product of phosphoinositide 3-kinases 
(PI3Ks), phosphatidylinositol 3,4,5-trisphosphate 
(PI[3,4,5]P3), controls key signaling pathways 
that are fundamental for the growth, prolifera-
tion, and differentiation of normal thymocytes 
and mature T lymphocytes. PI(3,4,5)P3 binds 
to pleckstrin homology domains in multiple sig-
naling molecules and either allosterically regu-
lates their catalytic activity or controls their 
intracellular trafficking. PI(3,4,5)P3 binding 
proteins in T cells include Tec family tyrosine 
kinases, guanine nucleotide exchange proteins 
for Rho family GTPases, and the essential serine/
threonine kinases phosphoinositide-dependent 
kinase l (PDK1) and protein kinase B (PKB) or 
Akt (Okkenhaug and Vanhaesebroeck, 2003). 
The PDK1–PKB signaling axis is fundamen-
tally important for normal thymocytes because 
it regulates protein synthesis, cell growth, and 
cell cycle progression via control of glycoly-
sis and nutrient uptake (Rathmell et al., 2003; 
Plas and Thompson, 2005; Cornish et al., 2006; 
Kelly et al., 2007). PI(3,4,5)P3 signaling via 
mammalian target of rapamycin (mTOR) and 
Foxo family transcription factors also controls 
lymphocyte trafficking by determining the 
repertoire of adhesion and chemokine receptors 
expressed by T lymphocytes (Fabre et al., 2008; 
Sinclair et al., 2008; Kerdiles et al., 2009).
PI3K signaling is not only important for 
normal lymphocyte physiology but also contrib-
utes to malignancies (Yuan and Cantley, 2008). 
In particular, phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN), which is a 
lipid phosphatase with specificity for the 3 posi-
tion of PI(3,4,5)P3 (Wishart and Dixon, 2002), 
is down-regulated by constitutive signaling by 
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In normal T cell progenitors, phosphoinositide-dependent kinase l (PDK1)–mediated phos-
phorylation and activation of protein kinase B (PKB) is essential for the phosphorylation 
and inactivation of Foxo family transcription factors, and also controls T cell growth and 
proliferation. The current study has characterized the role of PDK1 in the pathology caused 
by deletion of the tumor suppressor phosphatase and tensin homologue deleted on chromo-
some 10 (PTEN). PDK1 is shown to be essential for lymphomagenesis caused by deletion of 
PTEN in T cell progenitors. However, PTEN deletion bypasses the normal PDK1-controlled 
signaling pathways that determine thymocyte growth and proliferation. PDK1 does have 
important functions in PTEN-null thymocytes, notably to control the PKB–Foxo signaling 
axis and to direct the repertoire of adhesion and chemokine receptors expressed by PTEN-
null T cells. The results thus provide two novel insights concerning pathological signaling 
caused by PTEN loss in lymphocytes. First, PTEN deletion bypasses the normal PDK1- 
controlled metabolic checkpoints that determine cell growth and proliferation. Second, 
PDK1 determines the cohort of chemokine and adhesion receptors expressed by PTEN-null 
cells, thereby controlling their migratory capacity.
© 2009 Finlay et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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functions where PDK1 and PKB control nutrient receptor 
expression, cell growth, and proliferation. Our studies show 
that PTEN-null T cell progenitors cannot transform or de-
velop into invasive and fatal T lymphoma without PDK1. 
However, PDK1 and PKB did not control the pathological 
growth and proliferation of PTEN-null thymocytes. There 
was nevertheless an important role for PDK1, after PTEN 
deletion, to control the phosphorylation and activity of Foxo 
family transcription factors. PDK1 signaling also controlled 
expression of chemokine and adhesion receptors in PTEN-
null T cells and dictated their migratory capacity.
RESULTS
PTEN loss induces T lymphomagenesis via  
PDK1-dependent pathways
We used a mouse model to explore the role of PDK1 and 
PKB in T cell lymphomagenesis caused by PTEN deletion. 
Mice with PTEN alleles floxed by loxP Cre excision se-
quences were backcrossed to Lck-cre transgenic mice that ex-
press the Cre recombinase selectively in T cell progenitors in 
the thymus (Suzuki et al., 2001; Hagenbeek et al., 2004). These 
mice die at 13–14 wk because of aggressive T cell lymphomas 
(Suzuki et al., 2001; Hagenbeek et al., 2004; Hagenbeek and 
Spits, 2008). Fig. 1 A shows that the PTEN-null T lym-
phoma cells that develop in Ptenfl/fl Lck-cre mice have high 
constitutive levels of PDK1–PKB signaling compared with 
wild-type thymocytes as indicated by their high levels of PKB 
molecules phosphorylated on serine 473 and the PDK1 sub-
strate threonine 308 (Fig. 1 A). There are also high levels 
of phosphorylated PKB substrates Foxo1, 3a, and 4 in the 
PTEN-null T lymphomas (Fig. 1 A). In normal thymocytes, 
activation of PKB controls nutrient uptake and cell growth 
by inducing expression of nutrient receptors such as the trans-
ferrin receptor (CD71) and CD98, a key subunit of L-type 
amino acid transporters (Cornish et al., 2006; Kelly et al., 
2007). The majority of wild-type thymocytes, which do not 
contain active PKB, are thus predominantly small quiescent 
cells that lack expression of CD71 and CD98. In contrast, the 
T lymphoma cells isolated from Ptenfl/fl Lck-cre mice are uni-
formly large blastoid cells that express high levels of CD71 
and CD98 (Fig. 1 B).
To address the importance of PDK1 for T cell lymphoma-
genesis caused by PTEN deletion, we analyzed tumor devel-
opment in mice genetically engineered to simultaneously 
delete floxed PTEN and PDK1 in T cell progenitors. In these 
mice, the p56lck proximal promoter induces cre expression in T 
cell precursors before expression of the MHC receptors CD4 
and CD8 and completes deletion of floxed alleles by the double 
negative (DN) 3/4 stages of thymocyte development. Fig. 1 C 
compares survival kinetics of Ptenfl/fl Lck-cre mice and Ptenfl/fl 
PDK1fl/fl Lck-cre mice. Control wild-type mice remained 
healthy during the course of the study and typically have a life 
span of >24 mo (unpublished data). Ptenfl/fl Lck-cre mice devel-
oped massive T lymphomas and had a mean life span of 
13–14 wk (Fig. 1 C; Hagenbeek et al., 2004; Hagenbeek and 
Spits, 2008). When PTEN was deleted in T cell progenitors 
(Sulis et al., 2008). There is also evidence for microRNA-
mediated suppression of PTEN in lymphoma. The genomic 
region encoding the miR-17-92 microRNA cluster is often 
amplified in lymphomas, and miR-17-92 down-regulates ex-
pression of PTEN (Mendell, 2008; Xiao et al., 2008). PTEN 
is also deleted or mutated in a diverse range of solid human tu-
mors (Cantley and Neel, 1999), and its role as a tumor suppres-
sor has been confirmed by genetic studies in mice (Suzuki 
et al., 2008). PTEN haploinsufficient mice accordingly develop 
a wide range of tumors, including a high frequency of T lym-
phomas (Suzuki et al., 2008). Moreover, tissue-specific dele-
tion of PTEN in hematopoietic stem cells or thymocytes using 
Cre-loxP strategies results in T leukemogenesis or lymphoma-
genesis (Suzuki et al., 2001; Hagenbeek et al., 2004; Ma et al., 
2005; Yilmaz et al., 2006; Hagenbeek and Spits, 2008).
PTEN-null lymphoma/leukemic cells are large blastoid 
cells indicative of unrestrained activation of metabolic path-
ways (Suzuki et al., 2001; Hagenbeek et al., 2004; Hagenbeek 
and Spits, 2008). They are also very invasive and infiltrate 
peripheral tissues rather than restricting their homing to lym-
phoid organs. PTEN-null tumors accumulate PI(3,4,5)P3 and 
strongly activate PDK1–PKB signaling pathways. Moreover, 
PTEN haploinsufficient mice show reduced development of 
spontaneous tumors in many tissues if PKB alleles are deleted 
(Chen et al., 2006) or if PDK1 expression is reduced (Bayascas 
et al., 2005; Chen et al., 2006). There is thus evidence that 
PDK1 is important for the tumorogenesis caused by PTEN 
deletion, but the reason why PDK1 is important has not been 
explored. In normal T lymphocyte physiology, PDK1 and 
PKB control cell growth and proliferation (Hinton et al., 
2004; Fayard et al., 2007; Juntilla et al., 2007; Kelly et al., 
2007; Mao et al., 2007). It is therefore assumed that constitu-
tive PDK1–PKB signaling mediates the unrestrained metab-
olism, cell growth, and proliferation of PTEN-null T cells. 
On this basis, the PDK1–PKB signaling axis has been pro-
posed to be a suitable target for anticancer drug therapy 
(Garcia-Echeverria and Sellers, 2008; Peifer and Alessi, 2009). 
However, PTEN deletion alone does not result in cancer (Xue 
et al., 2008). PTEN-null tumors thus have secondary genetic 
alterations that are necessary for malignancy (Guo et al., 2008; 
Hagenbeek and Spits, 2008; Xue et al., 2008). Accordingly, 
the abnormal cell growth and proliferation of PTEN-null 
cells may not be a direct consequence of PI(3,4,5)P3 signal-
ing, but mediated by other pathways.
Understanding signaling pathways in nontransformed 
PTEN-null cells is crucial to understand how malignancy 
develops in cells with somatic loss or mutation of PTEN. 
Understanding the important signaling pathways in PTEN-null 
cells in vivo is also informative for the design of tumor thera-
pies. Accordingly, the aim of this study was to explore the 
role of PDK1 and PKB after PTEN deletion in an in vivo 
mouse model of T lymphomagenesis. The relevance of this 
work is that PTEN deletion causes robust activation of PDK1–
PKB signaling in T cells, but the precise role of this pathway 
has not been explored. It tends to be assumed that PTEN-
null T cells will just recapitulate the normal PDK1–PKB 
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2004; Kelly et al., 2007). In particular, PDK1 and PKB induce 
and maintain expression of the nutrient receptors CD71 and 
CD98, which control transferrin and amino acid uptake (Kelly 
et al., 2007). PKB also coordinates glucose uptake in T cells 
(Rathmell et al., 2003; Ciofani and Zuniga-Pflücker, 2005; 
Kelly et al., 2007; Jacobs et al., 2008). In the absence of PDK1 
or PKB, thymocytes cannot increase metabolism to match the 
energy demands of proliferation and hence they atrophy, go 
through cell cycle arrest, and ultimately die (Juntilla et al., 
2007; Kelly et al., 2007; Mao et al., 2007). In this context, 
Xue and colleagues (Xue et al., 2008) have suggested that 
normal thymocyte development is integral to lymphomagen-
esis in PTEN-null thymocytes (Xue et al., 2008). The PDK1 
requirement for transformation of PTEN-null thymocytes 
could therefore reflect that PDK1 activation of PKB is neces-
sary for nutrient receptor expression, cell growth and prolifer-
ation and thymic development of PTEN-deleted cells.
engineered to simultaneously delete PDK1, the majority of mice 
survived with no clinical signs of lymphomagenesis (Fig. 1 C). 
A low frequency of older Ptenfl/fl PDK1fl/fl Lck-cre mice did de-
velop T lymphomas, but these tumors consisted of cells that 
had failed to delete PDK1 alleles (Fig. 1 D). No PDK1-null 
tumors were ever observed in Ptenfl/fl PDK1fl/fl Lck-cre mice. 
Normally, PDK1-floxed alleles are efficiently deleted in T cell 
progenitors by the lck-driven Cre transgene (Fig. 1 D). How-
ever, the observation that the very rare tumors that develop in 
Ptenfl/fl PDK1fl/fl lck-Cre mice always contain nondeleted 
PDK1 alleles reveals that lymphomagenesis could only occur 
in PTEN-null cells that escaped PDK1 deletion.
PDK1 is obligatory for growth and proliferation  
of wild-type, but not PTEN-null, thymocytes
In normal T cell progenitors, PDK1 has essential functions in 
cell growth, proliferation, and differentiation (Hinton et al., 
Figure 1. PTEN loss induces T lymphomagenesis via PDK1-dependent pathways. (A) Western blot analysis of PKB and Foxo 1, 3a, and 4 phosphory-
lation in Ptenfl/fl Lck-cre thymic lymphoma cells versus total wild-type thymocytes. Data are representative of two separate experiments, three thymic 
lymphomas. (B) Cell size (FSC) and the expression of nutrient receptors CD71 and CD98 in total wild-type thymocytes compared with Ptenfl/fl Lck-cre thy-
mic lymphoma cells. Data are representative of three to five separate experiments; CD71 and CD98 (three mice), FSC (five mice). (C) Graph showing the 
development of tumors in Ptenfl/fl Lck-cre mice compared with wild-type and Ptenfl/fl Pdk1fl/fl Lck-cre mice (***, P = 0.0003, Ptenfl/fl Lck-cre versus Ptenfl/fl 
Pdk1fl/fl Lck-cre). Data are for nine mice from each genotype. (D) Genomic DNA was isolated from tumors that developed in Ptenfl/fl Pdk1fl/fl Lck-cre mice, 
and deletion of the floxed PDK1 allele was assessed by quantative real-time PCR. Genomic DNA from Pdk1fl/fl (minus Lck-cre) and Pdk1WT/WT mice were 
used as positive and negative controls, respectively. Data for tumors that developed in two separate Ptenfl/fl Pdk1fl/fl Lck-cre mice.
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In further experiments, we explored whether PDK1 is 
required for the growth and proliferation of PTEN-null cells. 
As discussed, in wild-type T cells, PDK1 is essential for cell 
growth and proliferation. We therefore compared cell size, 
proliferation, and differentiation of wild-type, PDK1-null, or 
PTEN/PDK1-null thymocytes isolated from PDK1+/+ 
Lck-cre, PDK1fl/fl Lck-cre, or Ptenfl/fl PDK1fl/fl Lck-cre mice. 
During normal thymocyte development, there are phases where 
cells undergo rapid proliferation and accordingly have increased 
metabolism and cell size. One such phase occurs in DN4 
thymocytes, which are large blastoid cells that express high 
levels of CD71 and CD98 (Fig. 2 D; Kelly et al., 2007). In 
contrast, and as described previously (Kelly et al., 2007), 
PDK1-null DN4 thymocytes are abnormally small with low 
To explore this possibility, we first assessed whether 
PTEN deletion and PKB activation was sufficient to induce 
growth (increase in cell mass) in T cells. Fig. 2 A shows that 
nontransformed thymocytes isolated from Ptenfl/fl Lck-cre 
mice have constitutively high levels of phosphorylated PKB 
and phosphorylated PKB substrates Foxo1, 3A, and 4. How-
ever, PTEN-null thymocytes are only slightly larger and have 
only slightly higher protein content compared with wild-
type control cells and are predominantly small cells compared 
with PTEN-null T lymphoma cells (Fig. 2, B and C). PTEN-
null thymocytes also fail to express universally high levels of 
CD71 and CD98, as seen on PTEN-null T lymphoma cells 
(Fig. 2 B). PDK1-mediated activation of PKB is thus not suf-
ficient to deregulate thymocyte growth.
Figure 2. PDK1 is obligatory for growth and proliferation of wild-type, but not PTEN-null, thymocytes. (A) Western blot analysis of PKB and Foxo1, 
3a, and 4 phosphorylation in Ptenfl/fl Lck-cre versus wild-type total thymocytes (top and bottom). Data are representative of four separate experiments, six 
sets of mice. (B) Cell size (FSC) and the expression of nutrient receptors CD71 and CD98 in total wild-type thymocytes compared with total Ptenfl/fl Lck-cre 
thymocytes. Data are representative of three to seven separate experiments; CD71 and CD98 (three mice), FSC (seven mice). (C) Protein concentration per cell, 
as determined by the Bradford assay, in wild-type, Ptenfl/fl Lck-cre total thymocytes, and Ptenfl/fl Lck-cre thymic lymphoma cells (*, P < 0.05; **, P < 0.01, vs. 
wild-type). Data are mean ± SEM of protein extracts made from three to seven separate experiments; Ptenfl/fl Lck-cre tumor (three mice), wild-type, and 
Ptenfl/fl Lck-cre total thymocytes (seven mice). (D) Cell size (FSC) and the expression of nutrient receptors CD71 and CD98 in wild-type versus Pdk1fl/fl Lck-cre DN4 
thymocytes. Data are representative of three separate experiments, three sets of mice. (E) Cell size (FSC) and the expression of nutrient receptors CD71 and 
CD98 in Pdk1fl/fl Lck-cre versus Ptenfl/fl Pdk1fl/fl Lck-cre DN4 thymocytes. Data are representative of three separate experiments, three sets of mice.
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is absolutely required for the DN-to-DP transition, and only 
cells that escape deletion of PDK1 can progress. In PTEN-
null cells, there is no such PDK1 dependency and hence no 
selective advantage for cells that fail to delete PDK1. PTEN-
null thymocytes can thus increase cell size, proliferate, and 
differentiate without PDK1.
The proliferation of PTEN-null T cell progenitors  
is dependent on RhoA
The ability of PTEN deletion to circumvent the normal 
PDK1/PKB requirement for T cell proliferation was surpris-
ing. In this context, it is known that PI(3,4,5)P3 signaling can 
also link to signaling pathways mediated by Rac/Rho family 
GTPases and these are also very important regulators of thy-
mocyte proliferation (Cleverley et al., 1999; Liliental et al., 
2000; Mullin et al., 2007). The key question then is does 
PTEN deletion bypass all the normal signaling pathways that 
control T cell development? The importance of RhoA for 
thymocytes was discovered by studies of transgenic mice that 
express Clostridium botulinum C3-transferase under the control 
of T cell–specific promoters (Cleverley et al., 1999). This 
toxin selectively ADP-ribosylates RhoA within its effector-
binding domain and abolishes its biological function. The ex-
pression of C3-transferase under the control of the CD2 locus 
control region (LCR) in T cell progenitors causes these cells to 
block in thymocyte differentiation at the DN3 stage such that 
adult CD2-C3 mice have a thymic phenotype indistinguish-
able from the phenotype of mice lacking key structural or sig-
naling components of preTCR complex, such as Rag2/ 
mice (Shinkai et al., 1992). We therefore assessed whether or 
not PTEN deletion could bypass the normal RhoA-controlled 
signaling pathways that control T cell proliferation. For these 
experiments, we compared the ability of PTEN deletion to 
induce proliferation of Rag2/ preT cells that lack expression 
of the preTCR complex and CD2-C3 preT cells that lack 
functional RhoA. The rationale for this comparison is that loss 
of Rag2 or inhibition of RhoA both block thymocyte differ-
entiation at the DN3 preT cell stage. As shown previously, 
PTEN deletion can induce a large proliferative expansion of 
Rag2/ preT cells (Fig. 3 F; Hagenbeek et al., 2004). How-
ever, PTEN deletion could not induce proliferative expansion 
of CD2-C3 preT cells (Fig. 3 F). Ptenfl/fl Lck-cre CD2-C3 
thymi are thus extremely small, comprising few cells. We con-
clude that PTEN deletion regulates thymocyte proliferation 
via RhoA-dependent pathways.
PDK1 controls the phosphorylation of Foxo transcription 
factors in PTEN-deleted T cells
The ability of PTEN-null thymocytes to bypass the normal 
PDK1/PKB requirements for cell growth and proliferation 
raises the question of whether other PKB signaling path-
ways function normally after PTEN loss. Here, it is relevant 
that PTEN-null T lymphoma cells have high levels of phos-
phorylated Foxo family transcription factors Foxo1, 3a, and 4 
(Fig. 1 A). These transcription factors act as tumor sup-
pressors in T cells, and deletion of Foxo1, 3a, and 4 mimics 
levels of the nutrient receptors CD71 and CD98 (Fig. 2 D). 
Strikingly, Ptenfl/fl PDK1fl/fl Lck-cre DN4 thymocytes had up-
regulated expression of CD98 and CD71, and the cells had 
returned to their normal size (Fig. 2 E). Thus, the expression 
of CD98 and CD71 in wild-type DN4s is PDK1 dependent, 
whereas the expression of these molecules in PTEN-null 
DN4s is PDK1 independent.
The inability of PDK1-null DN4s to maintain nutrient 
receptor expression prevents the cell growth and prolifer-
ation required for T cell differentiation (Kelly et al., 2007). 
Accordingly, PDK1-null T cell progenitors fail to develop 
beyond the DN4 stage (Hinton et al., 2004). PDK1fl/fl Lck-cre 
mice thus have small numbers of thymocytes compared with 
control mice, and these comprise mainly DNs (Fig. 3 A). 
Moreover, genomic PCR analysis shows that the few double 
positives (DPs) that appear in PDK1fl/fl Lck-cre thymi have 
failed to delete PDK1-floxed alleles (Fig. 3 B). We therefore 
questioned whether the ability of PTEN deletion to induce 
expression of nutrient receptors and restore cell size of PDK1-
null DN4s restored the capacity of this subset to proliferate 
and to generate DP and single-positive (SP) thymocytes? 
Here, the data show Ptenfl/fl PDK1fl/fl Lck-cre thymocyte 
numbers to be in the normal range (Fig. 3 A). PTEN deletion 
thus induces the growth and proliferation of T cell progeni-
tors independently of PDK1. Deletion of PTEN also induces 
DN to DP differentiation and the differentiation of mature 
SP thymocytes in the absence of PDK1 (Fig. 3 A). Moreover, 
peripheral T cell numbers in Ptenfl/fl PDK1fl/fl Lck-cre mice are 
normal (Fig. 3 C).
The restoration of cell size, proliferation, and differentia-
tion of Ptenfl/fl PDK1fl/fl Lck-cre thymocytes could be ex-
plained if loss of PTEN changed the timing of PDK1 deletion. 
A series of detailed and rigorous experiments have excluded 
this possibility. Importantly, genomic PCR analysis in Fig. 3 B 
shows that Ptenfl/fl PDK1fl/fl Lck-cre DP and SP thymocytes 
had successfully deleted PDK1 alleles. Hence the DPs and 
SPs that develop in Ptenfl/fl PDK1fl/fl Lck-cre mice were not 
cells that had “escaped” excision of PDK1 alleles. Western 
blot analysis also confirmed that Ptenfl/fl PDK1fl/fl Lck-cre thy-
mocytes had lost both PTEN and PDK1 protein (Fig. 3 D). 
In PDK1fl/fl Lck-Cre mice, there is loss of functional PDK1 
in DN4 thymocytes (Hinton et al., 2004). The critical exper-
iment showing that the timing of PDK1 loss is the same in 
Ptenfl/fl PDK1fl/fl Lck-cre mice is shown in Fig. 3 E. These data 
show there was functional loss of PDK1 in Ptenfl/fl PDK1fl/fl 
Lck-cre DN4 thymocytes as judged by the absence of phos-
phorylated S6 ribosomal subunits in these cells (Fig. 3 E). 
S6 phosphorylation is mediated by the 70-kD ribosomal S6 
kinase 1 (S6K1) which requires phosphorylation at its “T loop” 
site by PDK1. S6K1 has an additional requirement for PDK1 
function in that its activation is dependent on PKB regulation 
of mTOR activity. Fig. 3 E shows that S6 phosphorylation is 
high in wild-type DN4s, but absent after PDK1 deletion in 
both PTEN wild-type and PTEN-null DN4s. Therefore, 
PDK1 signaling is lost in Ptenfl/fl PDK1fl/fl Lck-cre DN4 thy-
mocytes. Hence, in normal thymocyte development, PDK1 
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Figure 3. Thymocytes that develop in Ptenfl/fl Pdk1fl/fl Lck-cre mice have efficiently deleted PDK1. (A) Histograms showing total and different 
thymocyte subset numbers in Pdk1+/+ Lck-cre, Pdk1fl/fl Lck-cre, and Ptenfl/fl Pdk1fl/fl Lck-cre mice. Data pooled from 6–15 separate experiments; Pdk1+/+ Lck-cre 
(12 mice), Pdk1fl/fl Lck-cre (6 mice), Ptenfl/fl Pdk1fl/fl Lck-cre (15 mice). (B) Genomic DNA was isolated from DPs and CD4 SPs sorted from Pdk1fl/fl Lck-cre and 
Ptenfl/fl Pdk1fl/fl Lck-cre mice, and the deletion of the floxed PDK1 allele was assessed by quantative real-time PCR. Data are from two separate experiments, 
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whether these changes were a direct consequence of PTEN 
deletion or a secondary consequence of cell transformation. 
To address this question, we examined CD62L and CCR7 
expression in thymocytes isolated from Ptenfl/fl Lck-cre mice 
before tumor development. The data show that PTEN de-
leted DP and SP thymocytes failed to normally up-regulate 
the expression of lymph node homing receptors CD62L and 
CCR7 (Fig. 4 C).
To determine whether the loss of these lymph node homing 
receptors is a direct consequence of the inactivation of Foxo 
transcription factors, we examined whether expression of a Foxo 
mutant with alanine substitutions at its PKB substrate sequences 
could restore expression of CD62L in PTEN-null T cells. In 
these experiments, we used a Foxo3a mutant with alanine sub-
stitutions at residues 32, 252, and 314 (Foxo3a AAA) that cannot 
be phosphorylated and inactivated by PKB (Burgering, 2008), 
and hence can restore Foxo transcriptional function in cells 
expressing active PKB. Fig. 4 D shows that PTEN-null T cells 
have low levels of CD62L surface expression, and this remains 
low if cells are infected with retroviral constructs expressing ei-
ther GFP alone or wild-type Foxo3a. However, cells expressing 
the GFP-tagged Foxo3a phospho mutant regained expression of 
CD62L. Therefore, restoring Foxo transcriptional activity is suf-
ficient for surface expression of the homing receptor CD62L, 
indicating that inactivation of Foxo transcription factors in 
PTEN-null thymocytes accounts for decreased surface expres-
sion of lymph node homing receptors.
It has been proposed that KLF2 suppresses the expression 
of inflammatory chemokine receptors such as CCR3 and 
CCR5 (Sebzda et al., 2008). Accordingly, KLF2-null quies-
cent peripheral T cells express abnormally high levels of CCR3 
and CCR5 and other inflammatory chemokine receptors. 
However, there was no evidence that the loss of KLF2 in 
PTEN-null T lymphomas or in PTEN-null nontransformed 
T cells caused abnormal expression of CCR3 or CCR5 (un-
published data). Nevertheless, PTEN-null T lymphomas ex-
press high levels of CD44 (Fig. 4 E; Hagenbeek and Spits, 
2008), an adhesion molecule normally up-regulated by lym-
phocyte activation, and one that has well characterized roles 
controlling extravasation of normal lymphocytes during in-
flammatory immune responses and in controlling the homing 
of leukemic stem cells (DeGrendele et al., 1997; Jin et al., 
2006; Krause et al., 2006; Hagenbeek and Spits, 2008). Strik-
ingly, increased expression of CD44 was an immediate con-
sequence of PTEN deletion. Fig. 4 F shows that PTEN 
the effect of PTEN deletion, resulting in T lymphoma de-
velopment (Paik et al., 2007). The abnormal growth and 
proliferation of PTEN-null T cells is not a direct conse-
quence of PTEN deletion. We therefore examined whether 
the phosphorylation of Foxos is a direct consequence of 
PTEN deletion and occurs in PTEN-null T cells before 
tumor development and whether this Foxo phosphorylation 
is mediated by PDK1 and PKB. Fig. 3 G compares Foxo 
phosphorylation in wild-type and PTEN-null thymocytes 
and shows that the latter contain high levels of phosphory-
lated Foxos. The loss of PTEN thus immediately results in 
Foxo phosphorylation (Fig. 3 G). Is the phosphorylation of 
Foxos in PTEN-null cells dependent on PDK1 and PKB? 
Fig. 3 G shows that Ptenfl/fl PDK1fl/fl Lck-cre thymocytes, 
which have deleted both PTEN and PDK1, do not express 
PKB molecules phosphorylated on Thr308 or Ser473 and 
do not contain phosphorylated Foxo1, 3a, and 4.
PTEN deletion disrupts expression of a network of adhesion 
molecules and chemokine receptors that control normal  
T cell trafficking
The aforementioned data reveal that PTEN deletion results in 
PDK1/PKB-mediated Foxo1, 3a, and 4 phosphorylation in 
T cells. Is this sufficient to cause loss of Foxo transcriptional 
activity? In quiescent normal lymphocytes, nonphosphorylated 
transcriptionally active Foxos control expression of Kruppel-
like factor 2 (KLF2), a transcription factor that regulates ex-
pression of the chemokine receptor CCR7 and the adhesion 
receptor CD62L that together control T cell transmigration 
from the blood across high endothelial venules into secondary 
lymphoid tissues (Carlson et al., 2006; Bai et al., 2007; Fabre 
et al., 2008; Sebzda et al., 2008; Sinclair et al., 2008; Kerdiles 
et al., 2009). The expression of these receptors is also con-
trolled by mTOR signaling (Sinclair et al., 2008), which is 
also triggered by PTEN loss. Accordingly, we examined 
PTEN-deleted T lymphoma cells and PTEN-deleted non-
transformed T cells for expression of the Foxo-regulated tar-
gets KLF2, CD62L, and CCR7. Fig. 4 (A and B) show that 
normal T cells express KLF2, have high levels of CCR7 and 
CD62L mRNA expression (Fig. 4 A), and have a high con-
centration of CD62L and CCR7 protein expressed on their 
cell surface (Fig. 4 B). In contrast, PTEN-null T lymphomas 
do not express KLF2, CCR7, and CD62L mRNA and have 
dramatically reduced levels of cell surface CD62L and CCR7 
(Fig. 4, A and B). It was however important to understand 
two sets of mice. (C) Histograms showing T cell number and frequency in the spleen and blood of Pdk1+/+ Lck-cre and Ptenfl/fl Pdk1fl/fl Lck-cre mice. Data 
pooled from three to nine separate experiments; spleen (three sets of mice), blood (nine sets of mice). (D) Western blot analysis of PTEN and PDK1 protein 
levels in total thymocytes from wild-type, Ptenfl/fl Lck-cre, and Ptenfl/fl Pdk1fl/fl Lck-cre mice. Data are representative of four separate experiments, six sets 
of mice. (E) Intracellular levels of phosphorylated S6 ribosomal protein in DN4 thymocytes from wild-type, Pdk1fl/fl Lck-cre, and Ptenfl/fl Pdk1fl/fl Lck-cre 
mice. DN4 thymocytes were treated with rapamycin (20 nM) for 20 min to give a negative control for phospho-S6 staining. Data are representative of 
three separate experiments, three sets of mice. (F) Thymic cellularity of Rag2/, Ptenfl/fl Rag2/ Lck-cre, CD2-C3, Ptenfl/fl CD2-C3 Lck-cre mice. Data are 
for 3–12 separate experiments; Rag2/ and Ptenfl/fl Rag2/ (3 mice), CD2-C3, and Ptenfl/fl CD2-C3 Lck-cre (12 mice). (G) Western blot analysis of PKB 
and Foxo transcription factor phosphorylation in total thymocytes from wild-type, Ptenfl/fl Lck-cre, and Ptenfl/fl Pdk1fl/fl Lck-cre mice. Data are representative of 
four separate experiments, six sets of mice.
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restored expression of the Foxo target genes CCR7 and CD62L 
in PTEN-null T cells and prevented up-regulation of CD44 
in response to PTEN deletion (Fig. 5 A). Hence, PDK1 con-
trols the repertoire of chemokine and adhesion receptors ex-
pressed by PTEN-deleted thymocytes; PTEN deletion can 
only subvert expression of CD62L, CCR7, and CD44 when 
PDK1 signaling is intact.
The tissue destination of lymphocytes is determined by 
the chemokine and adhesion receptors they express (Mora 
and von Andrian, 2006). CCR7 and CD62L are required for 
T cell homing to secondary lymphoid tissue, and CD44 con-
trols lymphocyte extravasation from the blood (Arbonés et al., 
1994; Förster et al., 1999; Cyster, 2005; Ebert et al., 2005; 
deletion causes a universal increase in CD44 expression in 
thymocytes from Ptenfl/fl Lck-cre mice. Moreover, high levels 
of CD44 were sustained as PTEN-null thymocytes progressed 
through development and matured into peripheral T cells.
PDK1 regulates expression of chemokine and adhesion 
receptors and regulates trafficking of PTEN-null T cells  
to secondary lymphoid tissue
Ptenfl/fl PDK1fl/fl Lck-cre thymocytes, that have deleted both 
PTEN and PDK1, do not express PKB molecules phosphory-
lated on Thr308 or Ser473 or phosphorylated Foxo1, 3a, 
and 4 (Fig. 3 G). The deletion of PDK1 should thus restore 
Foxo transcriptional activity. In this context, deletion of PDK1 
Figure 4. PTEN deletion disrupts normal expression of chemokine and adhesion receptors. (A) Analysis of mRNA expression in total wild-type 
thymocytes versus Ptenfl/fl Lck-cre thymic lymphoma cells. (B) Expression of CD62L and CCR7 on peripheral T lymphocytes from wild-type mice versus 
tumor-bearing Ptenfl/fl Lck-cre mice. (C) Analysis of CD62L and CCR7 expression on wild-type and Ptenfl/fl Lck-cre DP and CD4 SP thymocytes. (D) Ptenfl/fl 
Lck-cre splenic T cells were activated for 1 d with anti-CD3 (0.5 µg/ml), infected with retroviral constructs expressing GFP alone, GFP-tagged Foxo3a wild-
type, or GFP-tagged Foxo3a AAA, and cultured in IL-2 (20 ng/ml) for 2 d . GFP-positive cells were analyzed for expression of CD62L. Data are representa-
tive of two separate experiments. (E) Expression of CD44 on peripheral T lymphocytes from wild-type mice versus tumor-bearing Ptenfl/fl Lck-cre mice.  
(F) Analysis of CD44 expression on wild-type and Ptenfl/fl Lck-cre DP and CD4 SP thymocytes and peripheral T lymphocytes. (A−C and E) Data are mean ± SEM 
of three separate experiments, three sets of mice.
 o
n
 June 25, 2012
jem.rupress.org
D
ow
nloaded from
 
Published October 5, 2009
JEM VOL. 206, October 26, 2009 
ARTICLE
2449
Figure 5. PDK1 and Foxo family transcription factors control the trafficking of PTEN-null T cells. (A) Analysis of the expression of CCR7, 
CD62L, and CD44 on DP and CD4 SP thymocytes from wild-type, Ptenfl/fl Lck-cre, and Ptenfl/fl Pdk1fl/fl Lck-cre mice. Data are representative of three to four 
separate experiments; CCR7 (3 mice), CD62L and CD44 (4 mice). (B) Relative numbers of CD24 low mature SP thymocytes in wild-type, Ptenfl/fl Lck-cre and 
Ptenfl/fl Pdk1fl/fl Lck-cre thymi (*, P < 0.05; ns, nonsignificant vs. wild-type) Data for four separate experiments, four sets of mice. (C and D) Wild-type and 
Ptenfl/fl Lck-cre thymocytes were stained with CMTMR and CFSE, respectively, mixed at a 1:1 ratio, and transferred in to C57BL/6 hosts. After 2 h (C) or 18 h 
(D) the mice were sacrificed and the spleen, lymph nodes, blood (C and D), liver, and bone marrow were (D) analyzed for the presence of the transferred 
cells. Data show the number of wild-type (•) or Ptenfl/fl Lck-cre-labeled () SP thymocytes detected in each tissue (DP thymocytes in liver) as a percentage 
of total labeled cells recovered. Data are from three to nine mice and one to three separate experiments; 2 h (2 experiments); 18 h; (3 experiments); 
spleen 2 h and bone marrow 18 h (1 experiment; ***, P < 0.001; **, P < 0.01; ns, non significant). (E) Wild-type and Ptenfl/fl Pdk1fl/fl Lck-cre thymocytes were 
first analyzed to determine relative SP thymocyte numbers, then stained with CMTMR and CFSE, respectively. SP thymocytes mixed at a 1:1 ratio and 
transferred in to C57BL/6 hosts. After 18 h, the mice were sacrificed and the spleen and lymph nodes were analyzed for the presence of the transferred 
cells. Data show the number of wild-type (•) or Ptenfl/fl Pdk1fl/fl Lck-cre-labeled () SP thymocytes detected in each tissue as a percentage of total labeled 
cells recovered. Data are from two separate experiments, six mice (*, P < 0.05; **, P < 0.01). (F) Lymph node homing data from D and E normalized relative 
to wild-type and displayed side by side for direct comparison. •, Wild-type; , Ptenfl/fl Lck-cre; , Ptenfl/fl Pdk1fl/fl Lck-cre.
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reduced in numbers at these sites. Histological analysis showed 
that the few PTEN-null cells that could enter these secondary 
lymphoid tissues were found in the T cell areas (unpublished 
data). The PTEN-null cells had also disappeared from periph-
eral blood (Fig. 5 D). However, PTEN-null T cells and wild-
type T cells were both equally present in the liver (Fig. 5 D) 
and both could home to the bone marrow (Fig. 5 D).
The accumulation of mature SP cells in PTEN-null thymi 
(Fig. 5 B) and inability of PTEN-null T cells to transit from 
the blood to secondary lymphoid organs (Fig. 5, C and D) ar-
gues that PTEN loss can perturb the normal trafficking of 
T cells before cell transformation. This is consistent with the 
ability of PTEN loss to down-regulate expression of KLF2, 
CD62L, and CCR7. In PTEN/PDK1-null T cells expression 
of KLF2, CCR7, and CD62L is restored. Accordingly, we 
addressed whether the defects in PTEN-null T cells in terms 
of their ability to traffic from the blood to secondary lymphoid 
tissue is restored by PDK1 loss? Ptenfl/fl PDK1fl/fl Lck-cre or 
wild-type thymocytes were labeled with either CFSE or 
CMTMR, SP thymocytes mixed at a ratio of 1:1 and trans-
ferred into the tail vein of wild-type mice. After 18 h, lym-
phoid tissue was analyzed for the presence of the transferred 
cells. Both the wild-type and PTEN/PDK1-null T cells homed 
effectively to secondary lymphoid organs such as lymph nodes 
and spleen (Fig. 5 E). Cells were also detectable recirculating 
in the blood (unpublished data). Indeed, PTEN/PDK1-null 
cells showed moderately enhanced lymph node and spleen 
homing capacity relative to wild-type cells. The deletion of 
PDK1 in PTEN-null T cells thus restores their ability to traffic 
to secondary lymphoid tissue (Fig. 5 F) and maintains their re-
circulation through the blood.
DISCUSSION
The present study shows that PDK1 is essential for lympho-
magenesis caused by deletion of PTEN in T cell progenitors. 
In normal thymocytes, PDK1 activation of PKB is vital for 
cell growth and proliferation (Hinton et al., 2004; Kelly et al., 
2007) because PDK1 substrates such as PKB control the es-
sential metabolic responses that allow T cells to meet the en-
ergy demands of rapid proliferation. PTEN-null T lymphoma 
cells have high constitutive levels of PDK1/PKB signaling 
and are large, metabolically active blastoid cells that constitu-
tively express high levels of transferrin receptors (CD71) and 
L-type amino acid transporters (CD98). In normal lympho-
cytes, the expression of these nutrient receptors is controlled 
by PDK1 and PKB. However, although PTEN deletion 
caused an immediate strong activation of PKB in T cell pro-
genitors, the loss of PDK1 did not prevent expression of 
CD71 and CD98 in these cells. Moreover, growth and pro-
liferation of PTEN-null T cell progenitors is not dependent 
on PDK1, indicating that these cells can sustain sufficient me-
tabolism to support T cell proliferation. Collectively, these 
data indicate that the unrestrained growth and proliferation of 
PTEN-null T cells is not a direct effect of PTEN deletion and 
PKB stimulation but a secondary consequence of cell trans-
formation. Moreover, in PTEN-null cells, the PDK1/PKB 
Carlson et al., 2006; Mora and von Andrian, 2006; Sebzda 
et al., 2008). The changes in expression of these chemokine 
and adhesion molecules in PTEN-null cells raises the question 
of whether these cells would traffic normally? In this respect, 
the trafficking of PTEN-null T cells in vivo has not been 
explored previously, although we have reported that PTEN-
null thymi contain an increased frequency of CD24 low ma-
ture SP cells (Fig. 5 B; Sinclair et al., 2008). This accumulation 
of mature SP cells has also been seen in thymocytes that ex-
press constitutively active PI3K (Barbee and Alberola-Ila, 
2005) and reflects the observation that constitutive activation 
of PI3K promotes retention of mature T cells in the thymus. 
Importantly, deletion of PDK1 prevented the accumulation 
of CD24 low mature SP T cells in the thymus (Fig. 5 B).
What about the trafficking of PTEN-null T cells in the 
periphery? Here, it is important to note that in young PTEN-
null mice (4–6 wk), before tumor development, mature T 
lymphocytes are found in the spleen and lymph nodes (Xue 
et al., 2008). However, it is difficult to judge from this type 
of analysis whether PTEN-null T cells traffic normally in the 
periphery because T cell numbers in secondary lymphoid or-
gans are determined by a balance of the following factors: the 
efficiency of transendothelial migration from the blood into 
secondary lymphoid tissue; the homeostatic proliferation of 
peripheral T cells in the lymphopenic environment found in 
neonates (Min et al., 2002); and the rate at which cells egress 
secondary lymphoid tissue (Schwab and Cyster, 2007). In this 
respect, the enhanced survival and proliferative properties de-
scribed for PTEN-null peripheral T cells (Suzuki et al., 2001; 
Buckler et al., 2006) could mask any trafficking problems.
We therefore carefully examined the trafficking of PTEN-
null T cells between the blood and secondary lymphoid tissue. 
For these experiments, Ptenfl/fl Lck-cre or wild-type thymocytes 
were labeled with either CFSE or 5-(and-6)-(((4-chloromethyl) 
benzoyl)amino)tetramethylrhodamine (CMTMR), mixed at 
a ratio of 1:1 and directly transferred into the blood via tail vein 
injections into wild-type hosts. After 2 h, blood, lymph nodes, 
and spleen were analyzed for the presence of the transferred 
cells. This assesses the ability of the cells to undergo transendo-
thelial migration from the blood into secondary lymphoid tis-
sue. 2 h after transfer into the blood, PTEN-null T cells and 
wild-type T cells were equally present in the blood (Fig. 5 C). 
However, a striking difference was seen in the in vivo traffick-
ing of PTEN-null and wild-type T cells to lymphoid tissue 
(Fig. 5 C). Wild-type T cells could enter secondary lymphoid 
organs such as lymph nodes and spleen, whereas the corre-
sponding PTEN-null thymocytes were strikingly reduced in 
their capacity to enter lymph nodes and also had a reduced ca-
pacity to enter the spleen (Fig. 5 C). To further explore the 
trafficking of wild-type and PTEN-null cells the location of 
cells was explored 18 h after transfer into the tail veins. In these 
experiments, liver, blood, bone marrow, and lymphoid tissue 
were analyzed for the presence of the transferred cells. As with 
the 2-h time point, wild-type T cells were found in secondary 
lymphoid organs such as lymph nodes and spleen (Fig. 5 D), 
whereas the corresponding PTEN-null cells were strikingly 
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in lymphoid tissues (Cyster, 2005; Ebert et al., 2005; Carlson 
et al., 2006; Sebzda et al., 2008). PTEN loss also caused up-
regulation of CD44, an adhesion molecule that plays an im-
portant role in leukocyte extravasation from the blood during 
inflammatory immune responses and controls abnormal ad-
hesion of malignant cells (DeGrendele et al., 1997; Jin et al., 
2006; Krause et al., 2006). The present data demonstrate that 
the changes in the expression of trafficking receptors that 
occur in PTEN-null cells are mediated by PDK1 signaling. 
Consequently, deletion of PDK1 restored expression of CD62L 
and CCR7 and prevented the up-regulation of CD44 in 
PTEN-deleted T cells. Importantly, PTEN-null T cells also 
showed defective trafficking from blood into secondary lym-
phoid tissue, but this defect was rescued by removal of PDK1. 
PDK1 thus controls the migratory capacity of PTEN-null 
T cells. In this context, PTEN induced T lymphomas are inva-
sive tumors that originate in the thymus but cause morbidity 
when they disseminate to the periphery and extensively infil-
trate multiple tissues including the spleen, liver, kidney, and 
bone marrow (Suzuki et al., 2001; Hagenbeek et al., 2004). 
The previous idea of how PTEN might control cell adhesion 
and motility is that PI(3,4,5)P3 signaling regulates the GTPases 
Rac and RhoA and coordinates actin and microtubule 
dynamics (Reif et al., 1996; Liliental et al., 2000). PTEN also 
has protein phosphatase activity that inhibits cell motility 
(Raftopoulou et al., 2004; Leslie et al., 2007). However, 
lymphocytes are intrinsically highly motile cells whose tissue 
destination is dictated by the subset of chemokine and adhe-
sion receptors they express. The present results showing that 
PTEN deletion activates PDK1-mediated signaling pathways 
that dictate the cohort of chemokine and adhesion receptors 
expressed by T cells thus offers a mechanism by which PTEN 
loss could direct the trafficking of transformed lymphocytes. 
Here, it is noteworthy that the migratory behavior of PTEN 
T lymphoma cells is reminiscent of the trafficking behavior of 
immune-activated effector T cells that have a reduced capac-
ity to home to secondary lymphoid tissues and migrate pref-
erentially to peripheral tissues. Such effector T cells traffic to 
peripheral tissues because they have high levels of PI(3,4,5)P3/
PDK1/PKB signaling that inactivates Foxos and switches off 
expression of KLF2, CD62L, and CCR7. The unrestrained 
activation of a normal signaling pathway that redirects the 
trafficking of effector T cells during an immune response 
could therefore contribute to the changes in the migratory 
capacity of PTEN-null T lymphomas.
In summary, the present study has described the role of 
PDK1 in the pathological signaling caused by deletion of 
PTEN in T cell progenitors. A surprising result is that PTEN 
deletion results in strong activation of PDK1/PKB, but by-
passes the normal PDK1 requirement for cell growth and 
proliferation of T cells. Nevertheless, an important function 
for PDK1 in PTEN-null T cells is to direct the activity of 
Foxo transcription factors and determines the repertoire of 
adhesion and chemokine receptors expressed by PTEN-null 
T cells. Hence only some physiological functions of PDK1 
are recapitulated in the pathological reprogramming of cells 
controlled metabolic checkpoint that functions during normal 
T cell physiology is bypassed. This result is surprising because 
it has been assumed that PDK1/PKB signaling pathways would 
be a good target for drugs to block metabolism and prolifera-
tive expansion of PTEN-null tumors (Garcia-Echeverria and 
Sellers, 2008; Peifer and Alessi, 2009). The present results 
showing that PTEN-null T cells can proliferate in vivo with-
out PDK1/PKB signaling argue that this idea needs further 
evaluation. In this context, multiple genetic events contribute 
to transformation in PTEN-null hematopoietic cells (Xue et al., 
2008) and one recurring event is the acquisition of chromo-
somal translocations that cause overexpression of c-myc 
(Guo et al., 2008). It is known that c-myc target genes include 
those with essential functions for cell metabolism and cell 
growth (DeBerardinis et al., 2008). For example CD71, the 
transferrin receptor and major mediator of iron uptake in 
mammalian cells, is a direct c-myc target gene (O’Donnell et al., 
2006). The autonomous growth of PTEN-null lymphoma 
cells could thus reflect that these cells have secondary genetic 
alterations that control cell metabolism, such as chromosomal 
translocations that increase cellular levels of c-myc.
In normal T cell progenitors, proliferation and differenti-
ation are dependent on both PDK1- and RhoA-dependent 
signaling pathways (Cleverley et al., 1999; Hinton et al., 2004; 
Kelly et al., 2007; Mullin et al., 2007). The present data show 
that PTEN-deleted thymocytes remain RhoA dependent for 
proliferation, but can proliferate and differentiate without 
PDK1 and active PKB. This reveals divergence of pathologi-
cal versus physiological signaling in PTEN-null cells and 
raises the question of why PDK1 is essential for T lympho-
magenesis if PTEN deletion bypasses the normal PDK1 de-
pendence of T lymphocyte proliferation? Here, the key 
insight from the present work is that PDK1 has an obligatory 
function in controlling the phosphorylation and transcrip-
tional inactivation of Foxo1, 3a, and 4 in PTEN-null cells. 
These Foxo transcription factors have redundant, but essen-
tial roles controlling apoptosis after cellular stress (Burgering, 
2008) and are powerful tumor suppressors in T cells (Paik et 
al., 2007; Tothova et al., 2007). Somatic deletion of Foxo1, 
3a, and 4 causes the rapid development of aggressive thy-
mic lymphomas that infiltrate multiple peripheral tissues in a 
response that phenocopies loss of PTEN (Paik et al., 2007). 
Deficits in Foxo family transcriptional activity promote lym-
phomagenesis by promoting cell survival and resistance to 
oxidative stress. PDK1/PKB-induced phosphorylation and 
inactivation of Foxos would confer similar survival advan-
tages that permit the subsequent genetic alterations that co-
operate with PTEN deletion to cause T lymphomagenesis.
One other discovery from this study is that PDK1 dictates 
the repertoire of adhesion and chemokine receptors expressed 
by PTEN-null T cells. It was striking that PTEN loss down-
regulated expression of the transcription factor KLF2 and its 
gene targets: CD62L/L-selectin, which plays a fundamental 
role controlling transmigration of T cells across high endo-
thelial venules (Arbonés et al., 1994), and the chemokine re-
ceptor CCR7, which controls lymphocyte entry and retention 
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thymocytes were defined as Thy-1+, TCR-hi and positive for either CD4 
or CD8 expression. Intracellular phospho-S6 levels in ex vivo thymocytes 
were assessed as previously described (Hinton et al., 2004).
Western blotting. Thymocytes were lysed on ice in NP-40 lysis buffer 
(50 mM Hepes, pH 7.4, 75 mM NaCl, 1% Nonidet P-40, 10 mM sodium 
fluoride, 10 mM iodoacetamide, 1 mM EDTA, 40 mM -glycerophosphate, 
protease inhibitors, 1 mM phenylmethylsulfonyl fluoride, and 100 µM 
sodium orthovanadate). Protein was separated by SDS-PAGE, transferred to 
nitrocellulose membrane, and detected by Western blot analysis using stan-
dard techniques. Antibodies were raised in sheep against full length human 
Foxo1 and the N terminus of human Foxo3a. Total PTEN antibody was 
purchased from Santa Cruz Biotechnology, Inc., total PDK1 was obtained 
from Millipore, and all other antibodies were purchased from Cell Signaling 
Technologies.
Quantitative real-time PCR. RNA was purified using the RNeasy RNA 
purification Mini kit (QIAGEN) and reverse-transcribed using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories). Genomic DNA was purified 
using the Ready PCR DNA column kit as per manufacturer’s instructions 
(Flowgen Bioscience). Quantitative PCR was performed in 96-well plate 
format using iQ SYBR Green based detection (Bio-Rad Laboratories) on a 
BioRad iCycler. For mRNA analysis GAPDH, 18S, and HPRT mRNA 
levels were used for normalization and the derived values averaged. For 
genomic DNA analysis genomic GAPDH DNA levels were used for 
normalization.
Primers. PDK1 flox for: 5-ATCCCAAGTTACTGAGTTGTGTTGG-
AAG-3; PDK1 flox rev: 5-GTATGCTATACGAAGTTATAGCTTCA-
GGAAG-3; GAPDH forward: 5-CATGGCCTTCCGTGTTCCTA-3; 
GAPDH reverse: 5-CCTGCTTCACCACCTTCTTGAT-3; HPRT for-
ward: 5-TGATCAGTCAACGGGGGACA-3; HPRT reverse: 5-TTC-
GAGAGGTCCTTTTCACCA-3; KLF2 forward: 5-TGTGAGAAA-
TGCCTTTGAGTTTACTG-3; KLF2 reverse: 5-CCCTTATAGAA-
ATACAATCGGTCATAGTC-3; CD62L forward: 5-ACGGGCCCC-
AGTGTCAGTATGTG-3; CD62L reverse: 5-TGAGAAATGCCAGC-
CCCGAGAA-3; CCR7 forward: 5-CAGCCTTCCTGTGTGATT-
TCTACA-3; CCR7 reverse: 5-ACCACCAGCACGTTTTTCCT-3; 
18S forward: 5-ATCAGATACCGTCGTAGTTCCG-3; 18S reverse: 
5-TCCGTCAATTCCTTTAAGTTTCAGC-3.
Adoptive transfer. Thymocytes were isolated from Ptenfl/fl Lck-cre+/, 
Ptenfl/fl PDK1fl/fl Lck-cre+/ mice and wild-type mice. Thymocytes of one 
genotype were loaded with CellTracker Orange (CMTMR; Invitrogen), 
and the other genotype was loaded with CFSE (Invitrogen). For experi-
ments comparing Ptenfl/fl Lck-cre+/ versus wild-type, total thymocytes were 
mixed equally and injected into the tail vein of C57BL/6 mice. For experi-
ments comparing Ptenfl/fl PDK1fl/fl Lck-cre+/ and wild-type homing, num-
bers of SP thymocytes were ascertained and mixed at 1:1 ratio before 
injection. 2 or 18 h after injection the mice were sacrificed and liver, blood, 
spleen, and lymph nodes were removed for analysis. The number of Ptenfl/fl 
Lck-cre+/ or Ptenfl/fl PDK1fl/fl- Lck-cre+/-labeled thymocytes recovered and 
the number of labeled wild-type thymocytes recovered were expressed as a 
percentage of the total number of recovered cells.
Virus production and T cell infection. Phoenix ecotropic packaging 
cells (Stanford University) were transfected with 5-10 µg of pBMN-GFP 
(Orbigen) plasmid (empty vector, Foxo3a Wild-type, or Foxo3a AAA) using 
a standard calcium-phosphate transfection protocol. Approximately 12–18 h 
after transfection the media was discarded and fresh media added to the 
dishes. After an additional 24 h, incubation retroviral supernatants were col-
lected and spun briefly (1,500 rpm, 5 min) to sediment and remove packag-
ing cells. The supernatant was transferred to fresh tubes and viral particles 
were concentrated by high-speed centrifugation (20,000 g, 4 h). After cen-
trifugation, supernatant was discarded and concentrated viral particles were 
that accompanies loss of PTEN. These data argue that PDK1/
PKB inhibitors may not be as useful to prevent tumor cell 
proliferation in vivo as thought; instead, inhibitors of RhoA 
signaling may be more valuable. However, the fact that PTEN-
null cells can be dependent on PDK1 to regulate adhesion 
and chemokine receptor expression could indicate that PDK1/
PKB inhibitors may be useful to prevent any abnormal tissue 
dissemination of PTEN-null T lymphomas. Moreover, tu-
mor cells have to survive hypoxic condition once they dis-
seminate to peripheral tissue and a role for PDK1/PKB in 
regulating cell survival under hypoxic conditions may be im-
portant. Equally, it cannot be excluded that PTEN-null tu-
mors arise from cells that do need PDK1 for proliferation but 
that these are present at too low a frequency in the thymus 
for us to detect. However, if the aim of targeting PDK1 and 
PKB in tumors is to hit a metabolic checkpoint, the present 
results showing that PTEN can bypass a PDK1/PKB-con-
trolled metabolic checkpoint that functions during normal T 
cell physiology could be an indication that drug strategies that 
target metabolic enzymes more directly would be more valu-
able tumor therapies. Such drugs would circumvent any is-
sues of redundancy or compensation in terms of signaling 
molecules such as PDK1/PKB.
MATERIALS AND METHODS
Mice and cells. Mice were maintained in specific pathogen–free conditions 
under Home Office project licenses PPL60/3116 and PPL60/3812. Ptenfl/fl 
(Marino et al., 2002), PDK1fl/fl (Mora et al., 2003), Lck-cre (Takahama et al., 
1998), Rag2/(Shinkai et al., 1992), and transgenic CD2-C3 (Cleverley et al., 
1999) mice were bred and maintained in the Wellcome Trust Biocentre/
Transgenics Resource Unit, University of Dundee in compliance with UK 
Home Office Animals (Scientific Procedures) Act 1986 guidelines. Ptenfl/fl 
Lck-cre+/ and PDK1fl/fl Lck-cre+/ mice were generated as described previ-
ously (Hagenbeek et al., 2004; Hinton et al., 2004). Ptenfl/fl Lck-cre+/ were 
generated by crossing mice with floxed PTEN alleles, floxed PDK1 alleles, 
and mice expressing Cre recombinase under the control of the proximal p56lck 
promoter (Lck-cre+/). Ptenfl/fl Lck-cre+/ CD2-C3 mice were generated by 
crossing Ptenfl/fl Lck-cre+/ mice with transgenic CD2-C3 mice that selec-
tively express the bacterial toxin C3-transferase in thymocyte progenitors un-
der the control of CD2 promoter. Wild-type mice used as controls were either 
wild-type Lck-cre+/ or mice negative for Cre recombinase with various 
PTEN and PDK1 floxed alleles. When studying normal PTEN-null T cells, 
to ensure the absence of transformed T cells, experiments were performed 
using mice between 4 and 5 wk of age. Rag2/, Rag2/ Ptenfl/fl Lck-cre+/, 
CD2-C3, and CD2-C3 Ptenfl/fl Lck-cre+/ mice used were 6 wk of age.
Flow cytometric analysis. Antibodies conjugated to FITC, PE, allophy-
cocyanin (APC), and biotin were obtained from either BD or eBioscience. 
TriColor and APC Alexa Fluor 750–conjugated antibodies were obtained 
from Invitrogen. Cells were stained for surface expression of the following 
markers using the antibodies in parentheses: CD4 (RM4-5), CD8 (53–6.7), 
CD25 (7D4), CD44 (IM7), CD71 (C2), CD98 (RL388), CD62L (MEL-14), 
Thy1.2 (53–2.1), Thy1.1 (HIS51), TCR- (H57-597), CD16/CD32 
(2.4G2) (Fc Block), and TCR / (GL3). Cells were stained with saturating 
concentrations of antibody in accordance with the manufacturer’s instruc-
tions. For CCR7 staining, cells were labeled with mouse CCL19-Fc and 
detected using PE conjugated anti–human Fc (both from eBioscience). 
CD4 and CD8 DN subsets were gated by lineage exclusion of all thymocytes 
expressing CD4, CD8, or TCR /. DN3s and DN4s were further defined 
as CD25+CD44 and CD25CD44 thymocytes, respectively. Mature SP 
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